Roché Group Results
The Roché Group reported sales growth of 1% and a core operating profit decline of 4% at constant exchange rates (CER) in 2023.
IFRS net income increased by 7% while Core EPS increased by 6% at CER.
Pharmaceuticals Division
Sales in the Pharmaceuticals Division were CHF 44.6 billion, an increase of 6% at CER, driven by growing demand for newer medicines.
The Diagnostics Division reported sales of CHF 14.1 billion, a decline of 13% at CER due to lower sales of COVID-19-related tests.
The division’s base business grew by 4% at CER and across all regions, with immunodiagnostics being the main growth driver.
Manual:
Download: Roché Group Finance Report 2023
Chat: Powered By VoiceSphere